Skip to main content
. 2022 Jan 29;71(9):2067–2075. doi: 10.1007/s00262-021-03130-z

Fig. 2.

Fig. 2

PD-1/PDL-1 immune checkpoint in tumorigenesis (Panel A). PD-1/PDL-1 blockade by targeted antibodies and specific inhibitors (Panel B)